Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)J. Jean Cui, Martin P. Edwards, Michelle Tran‐Dubé et al.|Journal of Medicinal Chemistry|2011Cited by 924
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant MutationsTed W. Johnson, Martin P. Edwards, Paul Richardson et al.|Journal of Medicinal Chemistry|2014Cited by 587
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to CrizotinibQinhua Huang, Martin P. Edwards, Ted W. Johnson et al.|Journal of Medicinal Chemistry|2014Cited by 118
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung CancerMi Ran Yun, Byoung Chul Cho, Seok‐Gu Kang et al.|Clinical Cancer Research|2020Cited by 116
Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.Ted W. Johnson, Helen Y. Zou, Simon Bailey et al.|Molecular Cancer Therapeutics|2013Cited by 4